

Prior Authorization Criteria
Cerezyme (Imiglucerase)

All requests for Cerezyme (Imiglucerase) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Coverage may be provided with a diagnosis of Type 1 Gaucher Disease and the following criteria is met:

- Confirmation of Type I Gaucher Disease diagnosis by one of the following:
 - A beta-glucosidase leukocyte (BGL) test
 - A genetic test
- The member must be 2 years of age or older
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- Member must also have one or more of the following (supported by the corresponding documentation):
 - Anemia
 - Documentation of a baseline low hemoglobin level (laboratory reference range must be submitted)
 - Thrombocytopenia
 - Documentation of a baseline low platelet level (laboratory reference range must be submitted)
 - A provider attestation that the member has one of the following:
 - Bone disease
 - Hepatomegaly or splenomegaly supported by documentation of a current baseline liver or spleen size
- **Initial Duration of Approval:** 6 month duration.
- **Reauthorization criteria**
 - Documentation the member had a positive clinical response or stabilization as demonstrated by one of the following:
 - An increase in hemoglobin level from baseline (taken within the last 6 months)
 - An increase in platelet levels from baseline (taken within the last 6 months)
 - An attestation from the provider of an improvement in bone disease
 - A reduction in liver or spleen size from baseline (taken yearly)
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.



Updated: 01/2019
PARP Approved: 01/2019

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.

**CEREZYME (IMIGLUCERASE)
PRIOR AUTHORIZATION FORM**

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Gateway HealthSM Pharmacy Services. **FAX:** (888) 245-2049
If needed, you may call to speak to a Pharmacy Services Representative.
PHONE: (800) 392-1147 Monday through Friday 8:30am to 5:00pm

PROVIDER INFORMATION

Requesting Provider:	NPI:
Provider Specialty:	Office Contact:
Office Address:	Office Phone:
	Office Fax:

MEMBER INFORMATION

Member Name:	DOB:
Gateway ID:	Member weight: _____ pounds or _____ kg

REQUESTED DRUG INFORMATION

Medication:	Strength:
Frequency:	Duration:
Is the member currently receiving requested medication? <input type="checkbox"/> Yes <input type="checkbox"/> No	Date Medication Initiated:

Billing Information

This medication will be billed: at a pharmacy **OR**
 medically (if medically please provide a
JCODE: _____
Place of Service: Hospital Provider's office Member's home Other

Place of Service Information

Name:	NPI:
Address:	Phone:

MEDICAL HISTORY (Complete for ALL requests)

Diagnosis: Type 1 Gaucher Disease Other: _____ **ICD-10 code:** _____

If requesting for Type 1 Gaucher Disease how was the diagnosis confirmed? Please provide supporting documentation

Beta-glucosidase leukocyte (BGL) test Genetic Testing

Does the member have any of the following: please select all that apply

- Anemia
- Thrombocytopenia
- Bone Disease
- Hepatomegaly or splenomegaly

Please provide the following and laboratory reference range:

Baseline hemoglobin level: _____ Date taken: _____
Baseline platelet level: _____ Date taken: _____
Baseline spleen size: _____ Date taken: _____

Baseline liver size: _____ Date taken: _____

CURRENT or PREVIOUS THERAPY

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)

REAUTHORIZATION

Has the member tolerated therapy and shown improvement Yes No

1. If the member has bone disease has the member shown improvement Yes No N/A

2. Please provide the following:

Current hemoglobin level: _____ Date taken: _____

Current platelet level: _____ Date taken: _____

Current spleen size: _____ Date taken: _____

Current liver size: _____ Date taken: _____

SUPPORTING INFORMATION or CLINICAL RATIONALE

Prescribing Provider Signature

Date

--	--